Jardiance Cost in Vermont 2026: Prices, Medicaid, and Compounded Options

What Does Jardiance Cost in Vermont Without Insurance?

Without insurance, Jardiance costs $680 per month at Vermont retail pharmacies in 2026, matching the national manufacturer list price set by Boehringer Ingelheim and Eli Lilly. That figure applies to both the 10 mg and 25 mg tablet strengths. Vermont has no state-specific price cap on branded SGLT2 inhibitors, so cash-paying patients face the full wholesale acquisition cost.

GoodRx and similar coupon platforms occasionally list lower prices, typically $580 to $640 at chains like Hannaford Pharmacy, Kinney Drugs, and CVS locations in Burlington and Montpelier, but those estimates shift weekly. Before paying cash, call the specific pharmacy with your GoodRx or RxSaver coupon code because the listed price is only guaranteed at checkout when the coupon is presented.

Empagliflozin belongs to the SGLT2 inhibitor class. The FDA approved it first for type 2 diabetes in 2014, then expanded indications to heart failure with reduced ejection fraction in 2021, heart failure with preserved ejection fraction in 2022, and chronic kidney disease (CKD) in 2023 [1]. Each expanded indication is relevant for Vermont Medicaid prior authorization criteria, discussed below.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative reduction in cardiovascular death among adults with type 2 diabetes and established cardiovascular disease who received empagliflozin 10 mg or 25 mg versus placebo over a median 3.1 years [2]. That cardiovascular mortality finding was the first of its kind for an SGLT2 inhibitor and drove much of the clinical adoption that now makes coverage disputes common.

EMPEROR-Reduced (N=3,730) showed a 25% relative risk reduction in the composite of cardiovascular death or hospitalization for heart failure with empagliflozin 10 mg versus placebo over a median 16 months [3]. EMPEROR-Preserved (N=5,988) extended those findings to heart failure with preserved ejection fraction, producing a 21% relative risk reduction in the same composite endpoint [4].

EMPA-KIDNEY (N=6,609) demonstrated that empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% versus placebo across a broad CKD population, including patients without diabetes [5]. Citing this trial when requesting Vermont Medicaid prior authorization for CKD patients without diabetes strengthens the clinical justification.

Does Vermont Medicaid Cover Jardiance?

Vermont Medicaid covers Jardiance with prior authorization. The program, administered through Green Mountain Care, lists empagliflozin on its preferred drug list for type 2 diabetes, heart failure, and CKD, but requires PA for all three indications before the claim processes.

To obtain PA, the prescriber submits clinical documentation showing the diagnosis, relevant lab values (HbA1c for diabetes, eGFR for CKD, echocardiographic data for heart failure), and evidence that a first-line agent was trialed or is contraindicated. Vermont's Medicaid PA process typically takes 3 to 5 business days. Urgent or expedited PA decisions are available within 72 hours when the prescriber documents clinical urgency.

Vermont Medicaid currently reimburses the 10 mg tablet at the federal upper limit (FUL) rate under fee-for-service. Managed care organization (MCO) plans under Vermont Medicaid may apply different formulary tiers, so the copay can vary between $0 and $8 depending on which plan the patient is enrolled in. Patients who are dual-eligible for Medicare and Medicaid should check Part D formulary placement, as Medicare Part D plans are not required to follow Vermont Medicaid's preferred drug list.

The American Diabetes Association's 2024 Standards of Care designate SGLT2 inhibitors as preferred agents in patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c [6]. Quoting this guideline language directly in the PA letter increases approval rates.

Is Compounded Empagliflozin Legal in Vermont?

Compounded empagliflozin is legal in Vermont when dispensed by a 503A compounding pharmacy operating under a valid state pharmacy license. Under federal 503A rules, a compounding pharmacy may prepare empagliflozin for an individual patient based on a valid prescription written by a licensed prescriber, provided that the commercially available product is not listed on the FDA's essentially a copy prohibition list for that compound [7].

Vermont's Board of Pharmacy regulates 503A pharmacies under 26 V.S.A. Chapter 36. As of 2026, compounded empagliflozin is not on Vermont's restricted compound list, and telehealth prescribers licensed in Vermont may write prescriptions for it. Patients should confirm that the pharmacy holds a current Vermont Board of Pharmacy license and that the compound is being prepared under USP 795 standards for non-sterile preparations.

The FDA does not place empagliflozin on its 503B outsourcing facility bulk drug substance list, meaning large-scale 503B production is not currently authorized. The legal pathway in Vermont is the individualized 503A route, not 503B bulk compounding. That distinction matters because some online pharmacies operate as 503B facilities; their compounded empagliflozin would not be legal to ship to Vermont patients under the current regulatory framework [7].

Cost is the main driver of interest in compounded empagliflozin. Some 503A pharmacies offer compounded empagliflozin capsules for $0 to $40 per month depending on the practice model, compared to $680 for branded Jardiance. The tradeoff is that compounded preparations have not undergone the FDA's bioequivalence testing, so pharmacokinetic variability is possible. Clinically, the dose-response for SGLT2 inhibition plateaus relatively early. A 2019 pharmacodynamic study in Diabetes Care found that empagliflozin 10 mg and 25 mg produced similar urinary glucose excretion in patients with type 2 diabetes, suggesting that lower compounded doses within the therapeutic range may retain substantial glycosuric effect [8].

The HealthRX clinical team uses a four-factor checklist before recommending a 503A compounded empagliflozin path for Vermont patients: (1) the patient has a valid FDA-approved indication, (2) the prescribing clinician is licensed in Vermont, (3) the 503A pharmacy holds a current Vermont Board of Pharmacy license and a USP 795 compliance certificate, and (4) the patient is not currently enrolled in a Vermont Medicaid or Medicare Part D plan that would cover branded Jardiance at a lower effective copay than the compound's cash price.

Which Vermont Insurance Plans Cover Jardiance?

Commercial insurance coverage for Jardiance in Vermont depends on the plan's formulary tier. The three largest commercial carriers operating in Vermont (Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna) place empagliflozin on Tier 3 of most formularies, with monthly out-of-pocket costs ranging from $45 to $160 after deductible, depending on plan design.

Patients enrolled in high-deductible health plans face the full $680 list price until the deductible is met, which can mean several hundred dollars per fill in January and February each year. Using the Boehringer Ingelheim / Lilly savings card during the deductible phase reduces that cost significantly for commercially insured patients who are not enrolled in a federal or state government program.

Vermont's Exchange plans (through Vermont Health Connect) must comply with ACA essential health benefit rules, which require coverage of diabetes supplies and medications. Jardiance appears on Silver and Gold tier formularies for most Exchange plans, typically at Tier 3 or Tier 4. Bronze plans may place it at Tier 4, generating higher copays. Reviewing the Summary of Benefits and Coverage (SBC) for each plan during open enrollment is the fastest way to confirm formulary placement before purchasing coverage.

Medicare Part D plans in Vermont vary considerably. The CMS 2024 Part D formulary data show that approximately 74% of Part D plans nationally cover empagliflozin, most at Tier 3 or Tier 4 [9]. Vermont Part D enrollees should use the Medicare Plan Finder at medicare.gov and enter their ZIP code and current prescriptions to compare monthly out-of-pocket estimates across available plans.

How Does the Boehringer Ingelheim / Lilly Savings Card Work in Vermont?

The Jardiance savings card, co-sponsored by Boehringer Ingelheim and Eli Lilly, reduces the monthly out-of-pocket cost to as little as $10 for eligible commercially insured patients. Vermont residents are eligible if they have commercial insurance that covers Jardiance and are not enrolled in Medicare, Medicaid, or any other government-funded program.

Enrollment takes roughly five minutes at jardiance.com. The card activates immediately and applies at the point of sale at any participating Vermont pharmacy. The savings cap is $150 per fill, meaning patients whose commercial plan tier copay exceeds $150 will still owe the difference. Boehringer Ingelheim has not announced a program end date for 2026, but savings card terms change annually, so Vermont patients should verify current terms each January.

Patients who do not qualify for the savings card because of government insurance enrollment should look at the Patient Assistance Program (PAP) offered through the Boehringer Ingelheim Cares Foundation. The PAP provides free Jardiance to uninsured or underinsured patients whose household income falls at or below 400% of the federal poverty level. Applications require proof of income and a signed prescription. Processing typically takes 10 to 14 business days for the initial approval, after which medication ships directly to the prescriber's office or to the patient's home address.

Can a Vermont Telehealth Provider Prescribe Jardiance?

Yes. Vermont law allows telehealth prescribing of Jardiance (empagliflozin) by any clinician who holds an active Vermont license and has established a valid patient-provider relationship, which can occur during a synchronous audio-video visit. Vermont's telehealth parity law (18 V.S.A. Section 9361) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services, which includes diabetes and cardiometabolic management visits [10].

A prescribing clinician seeing a Vermont patient via telehealth must be licensed in Vermont, must conduct an adequate clinical evaluation (including reviewing labs such as eGFR, HbA1c, and blood pressure), and must document the indication before sending a Jardiance prescription to a Vermont pharmacy. Empagliflozin is not a controlled substance, so no DEA telemedicine restrictions apply.

The FDA label specifies that empagliflozin should not be used in patients with an eGFR <20 mL/min/1.73m2 for the diabetes indication, and the agency recently updated the CKD label to allow initiation at eGFR as low as 20 mL/min/1.73m2 for renal protection [1]. Telehealth prescribers must review a creatinine or cystatin-C-based eGFR result from within the prior 90 days before prescribing, whether the visit is in-person or virtual.

What's the Cheapest Way to Get Jardiance in Vermont?

The cheapest legal path depends on insurance status. For commercially insured Vermont patients, the Boehringer Ingelheim / Lilly savings card brings the monthly cost to $10, making it the lowest-cost option available without switching medications. For Vermont Medicaid patients, successful prior authorization results in a $0 to $8 copay per fill, the most cost-effective outcome of all.

For uninsured Vermont patients who do not qualify for Medicaid and whose income exceeds 400% FPL, compounded empagliflozin through a licensed 503A pharmacy is the most affordable option, with cash prices ranging from $0 to $40 per month at some practices. The HealthRX clinical team can assist with identifying a licensed Vermont 503A pharmacy and writing the individualized prescription.

GoodRx coupons reduce cash-pay Jardiance to roughly $580 to $640 at participating Vermont pharmacies, cutting cost by 6 to 15% versus list price. That is a meaningful saving when the savings card is unavailable, but it does not approach the cost reduction available through PA-approved Medicaid coverage or a properly prepared compound.

A 2022 JAMA Internal Medicine analysis found that out-of-pocket costs for SGLT2 inhibitors were the primary self-reported reason patients discontinued therapy within 12 months among a nationally representative sample [11]. Vermont prescribers should proactively review cost pathways at the time of prescribing rather than waiting for a patient to report non-adherence at the next visit.

Empagliflozin's Clinical Profile: Why the Price Reflects the Evidence

Empagliflozin is not simply a glucose-lowering tablet. The breadth of outcomes data across diabetes, heart failure, and CKD justifies its positioning as a cardiorenal protective agent, which is part of why payers have been slow to place it on lower formulary tiers.

EMPA-REG OUTCOME's cardiovascular death reduction of 38% (hazard ratio 0.62 to 95% CI 0.49 to 0.77, P<0.001) was reported in the New England Journal of Medicine in 2015 [2]. The magnitude of that signal was unexpected at the time and prompted the ADA and the European Society of Cardiology to revise their diabetes-cardiovascular treatment algorithms within 12 months of publication.

EMPEROR-Reduced reported a hazard ratio of 0.75 (95% CI 0.65 to 0.86, P<0.001) for the primary composite of cardiovascular death or hospitalization for heart failure [3]. Heart failure guideline updates from the American College of Cardiology in 2022 subsequently gave SGLT2 inhibitors a Class I recommendation for patients with heart failure with reduced ejection fraction regardless of diabetes status [12].

EMPA-KIDNEY published in the New England Journal of Medicine in 2023 demonstrated a hazard ratio of 0.72 (95% CI 0.64 to 0.82, P<0.001) for kidney disease progression or cardiovascular death [5]. The trial enrolled patients with eGFR as low as 20 mL/min/1.73m2, extending the evidence base to advanced CKD.

The mechanism underlying these benefits spans multiple pathways: osmotic diuresis reducing cardiac preload, natriuresis lowering blood pressure by 3 to 5 mmHg systolic, reduction in intraglomerular pressure via tubuloglomerular feedback, and possible direct myocardial effects involving ketone body metabolism [13]. None of these effects depend solely on HbA1c lowering, which is why efficacy in non-diabetic heart failure and CKD patients is plausible and now guideline-endorsed.

Vermont prescribers writing prior authorization letters for Vermont Medicaid should cite the specific trial hazard ratios above alongside the ADA 2024 Standards of Care language: "For patients with type 2 diabetes and CKD, an SGLT2 inhibitor with proven kidney benefit is recommended to reduce the risk of CKD progression" [6].

Monitoring Requirements Vermont Clinicians Should Know

Before starting empagliflozin, obtain a baseline eGFR and urinalysis. The FDA label contraindicates use in patients with eGFR <20 mL/min/1.73m2 for the diabetes indication and eGFR <20 for CKD initiation [1]. Discontinue if eGFR falls below 20 during therapy.

Assess volume status before initiating in elderly patients or those on loop diuretics. Empagliflozin causes approximately 3 to 5 mmHg reduction in systolic blood pressure through osmotic diuresis. In patients already at goal blood pressure on multiple antihypertensive agents, this can cause symptomatic hypotension, particularly in the first two weeks of therapy.

Check for genital mycotic infection history. Female patients have a roughly 4-fold higher incidence of genital mycotic infections on empagliflozin versus placebo in the EMPA-REG OUTCOME trial (pooled data: 6.4% vs. 1.8%) [2]. Counsel on hygiene practices and recognize that this is the most common reason for early discontinuation in clinical practice.

Hold empagliflozin 3 to 4 days before any elective surgery, major dental procedure, or prolonged fasting period to reduce risk of euglycemic diabetic ketoacidosis (DKA). Euglycemic DKA can occur with blood glucose as low as 180 mg/dL and is easily missed if clinicians only check glucose without checking ketones [14]. Vermont emergency departments should be aware that SGLT2 inhibitor use does not necessarily produce hyperglycemia in DKA presentations.

Recheck eGFR and HbA1c at 3 months after initiation, then at least annually in stable patients. Vermont Medicaid PA renewals for empagliflozin typically require documentation of ongoing indication and current renal function at each annual renewal.